Progentos Therapeutics Announces First Participant Dosed in Phase 1/2a Study of PRO‑1562 for Remyelination in Multiple Sclerosis

Progentos Therapeutics Announces First Participant Dosed in Phase 1/2a Study of PRO‑1562 for Remyelination in Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 3, 2026-

Progentos Therapeutics Announces First Participant Dosed in Phase I/IIa Study of PRO‑1562 for Remyelination in Multiple Sclerosis

Progentos Therapeutics announced that the first participant has been dosed in its Phase I/IIa clinical trial of PRO-1562 (NCT07826689), a novel oral small molecule designed to regenerate myelin in patients with demyelinating diseases, like multiple sclerosis. [Progentos Therapeutics] Press Release

Potential myelin sheath repair treatment for MS enters clinical trial

The first participant has been dosed in a Phase 1/2a clinical trial testing PRO-1562, an experimental oral treatment designed to repair myelin, the protective sheath around nerve fibers that is damaged in people with multiple sclerosis (MS). Developed by Progentos Therapeutics, PRO-1562 aims to help existing immature cells develop into myelin-producing cells, potentially restoring nerve […]